MedTrace Logo

A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure

NCT01125514 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2012-09-10

Study results available
· View outcomes & findings →

Summary

This study assessed the interaction between single and multiple doses of aliskiren (150 mg and 300 mg) and furosemide (60 mg) in patients with heart failure.

Conditions

Interventions

DRUG

Aliskiren 150 mg

Aliskiren 150 mg tablet

DRUG

Furosemide 60 mg

Furosemide 60 mg commercially-available tablets

DRUG

Placebo for Aliskiren

Matching placebo for aliskiren 150 mg and 300 mg

DRUG

Aliskiren 300 mg

Aliskiren 300 mg tablet

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • Germany
  • Lithuania

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01125514 on ClinicalTrials.gov